HAIFA, Israel, November 15 /PRNewswire/ -- InSightec announced today that it's ExAblate(R) 2000 technology will be featured in seven presentations at the 91st Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA). The meeting will be held at McCormick Place in Chicago, November 22 - December 2, 2005. The ExAblate 2000 combines magnetic resonance imaging (MRI) with high intensity focused ultrasound to non-invasively thermally ablate (destroy) tumors in the body. InSightec continues to develop this leading technology approved by the FDA last year for uterine fibroids and has launched a multi-million dollar program to conduct human clinical trials on the technology's potential use in treating other oncology indications including breast, bone, liver, and brain tumors while continuing the clinical research in fertility preserving treatment of uterine fibroids. The ExAblate 2000 is being used in 25 sites worldwide and has treated over 1400 women in the past year with uterine fibroids, a benign but painful condition that affects approximately 25% of women of childbearing age. In the oncology field, more than 130 patients with breast cancer were treated globally under research protocols. The ExAblate 2000 System will be exhibited at the GE Healthcare booth, #7714 in the North Hall. Also, Fiona Fennessy's studies on uterine fibroids have been selected by RSNA to be highlighted in a press conference on Wednesday, November 30 (please see details below). Following are the ExAblate 2000 talks and sessions at RSNA: Presentation Title/Abstract Presenter Date/Time/Location Number Feasibility of Atsuya Okada, Sunday, November 27 Diffusion-weighted MR Imaging MD, IseiKai and ADC Map to Predict Necrosis Hospital, 11:05 am - 11:15 am of Uterine Fibroids during MR Osaka, Japan Imaging-guided Focused E353A Ultrasound Surgery (SSA06-03) Magnetic Resonance guided Wadyslaw Sunday, November 27 focused ultrasound of Uterine Gedroyc, MD, Fibroids: Treating Larger St. Mary's 11:55 am - 12:15 pm Leiomyomas (SSA06-08) Hospital, London, England E353A Treatment Outcome in MR-guided Fiona Fennessy, Monday, November 28 Focused Ultrasound Surgery MD, Brigham and (MRgFUS) for Uterine Fibroids: Women's 11:10 am - 11:40 am Analysis of the Effect of Hospital, Baseline Uterine Size and Boston, MA E253CD Number of Fibroids (SSCO2-05) Evaluation of symptom relief Fiona Fennessy, Monday, November 28 and fibroid reduction one year MD, Brigham and following MR-guided Focused Women's 11:30 am - 11:40 am Ultrasound Surgery (SSCO2-07) Hospital, Boston, MA E253CD Novel Breast Therapies and Dave Monday, November 28 Techniques Gianfelice, MD, Toronto General 4:30 pm - 6:00 pm (Invited speaker). (SFF01) Hospital, E350 Toronto, Ontario, Canada RSNA Press Conference: Fiona Fennessy, Wednesday, Noninvasive Ultrasound MD, Brigham and November 30 Treatment Shrinks Fibroids Women's Hospital, 9:45 am Boston, MA Media Room (Level 2, Hall E) MR guided focused ultrasound Hidemi Thursday, December 1 ablation of breast cancer Furusawa, MD, (LPR01-04) Breastopia 12:45pm - 12:55 pm Namba Hospital, (Poster Session - Miyazaki, Japan Theater 2A) Interventional Oncology Kullervo Thursday, December 1 Symposium Session: Image Hynynen, PhD 1:40 pm - 2:00 pm guidance for Oncologic Brigham and Intervention MR guided focused Women's S101AB ultrasound interventions Hospital, Boston, MA Evaluation of Safety and Fiona Fennessy, Friday, December 2 Efficacy of a Continued Access MD, Brigham and 11:10 am - 11:20 am Study for MR-guided Focused Women's Ultrasound Surgery of uterine Hospital, E350 fibroids (SSTO2-05) Boston, MA About ExAblate 2000 The ExAblate 2000 is the first U.S. Food and Drug Administration (FDA) approved system to use the breakthrough MRgFUS technology that combines MRI - to visualize tissues in the body, plan the treatment and monitor in real time treatment outcome - and high intensity focused ultrasound to thermally ablate tissue. MR thermal feedback, provided uniquely by the system, allows the physician to control and adjust the treatment in real time to ensure that the targeted tumor is fully treated and surrounding tissue is spared. ExAblate received FDA approval for the treatment of symptomatic uterine fibroids in October 2004. Uterine fibroids are benign growths in the uterus that affect approximately 13 million women of child bearing age in the U.S. Each year approximately 200,000 women have hysterectomies, to treat uterine fibroids. Unlike hysterectomy, myomectomy and UAE, this technology is completely non-invasive using MR-guided focused ultrasound to thermally ablate (destroy) tumors in the uterus. For women this means no hospital stay and only 1-2 days of recovery as opposed to the one week (UAE); two weeks (myomectomy); or six weeks (hysterectomy) usually associated with treatment of this condition. About InSightec InSightec Ltd. is a privately held company owned by Elbit Medical Imaging (EMI), General Electric, MediTech Advisors, LLC and employees. It was founded in 1999 to develop the breakthrough MR guided Focused Ultrasound technology and transform it into the next generation operating room. Headquartered near Haifa, Israel, the company has over 135 employees and has invested more than $80 million in research, development, and clinical investigations. Its U.S. headquarters are located in Dallas, Texas. For more information, please go to: http://www.insightec.com For more information about uterine fibroids, please visit http://www.uterine-fibroids.org Contact Information InSightec Ltd. Tel: +972-4-813-1313 Email: email@example.com For media inquiries, contact: Fern Lazar Lazar Partners, Ltd. Tel: +1-212-867-1762 Email: firstname.lastname@example.org
SOURCE InSightec Ltd.